Experimental PAH drug trial halted early

NCT ID NCT05135000

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial was terminated early, meaning it likely did not show enough promise to continue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LTP001 (an experimental oral drug)
What this could lead to: If it had worked, LTP001 could have pointed toward a new treatment option for pulmonary arterial hypertension, a serious lung condition.
What could go wrong: The trial was terminated early, meaning it likely did not show enough benefit or had safety concerns. It was also a small Phase 2 study, so results are very preliminary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

Medical Univ of South Carolina

Charleston, South Carolina, 29425, United States
Novartis Investigative Site

Caba, Buenos Aires, C1025ABI, Argentina
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Amsterdam, 1081 HV, Netherlands
Novartis Investigative Site

Krakow, 31 202, Poland
Novartis Investigative Site

Lodz, 91-347, Poland
Novartis Investigative Site

Wroclaw, 50-556, Poland
Novartis Investigative Site

Málaga, Andalusia, 29010, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08036, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Novartis Investigative Site

London, SW3 6PH, United Kingdom
Pulmonary Associates PA

Mesa, Arizona, 85206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.